Histone Deacetylase Inhibitors as a Therapeutic Strategy to Eliminate Neoplastic “Stromal” Cells from Giant Cell Tumors of Bone

• Published in: Cancers Vol. 14; no. 19; p. 4708
• Main Authors: Venneker, Sanne, van Eenige, Robin, Kruisselbrink, Alwine B, Palubeckaitė, Ieva, Taliento, Alice E, Briaire-de Bruijn, Inge H, Hogendoorn, Pancras C. W, van de Sande, Michiel A. J, Gelderblom, Hans, Mei, Hailiang, Bovée, Judith V. M. G, Szuhai, Karoly
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 27.09.2022; MDPI
• Subjects: Acetylation; Apoptosis; Bone cancer; Bone tumors; Cell growth; Dosage and administration; Drug therapy; Enzyme inhibitors; Epigenetics; Gene expression; Germ cell tumors; Histone deacetylase; Histone H3; Isoforms; Kinases; Lesions; Ligands; Mutation; Neoplasia; Patients; Quality of life; Therapeutic targets; Transcriptomes; Tumors; Netherlands; United States > US
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14194708

The neoplastic “stromal” cells in giant cell tumor of bone (GCTB) harbor a mutation in the H3F3A gene, which causes alterations in the epigenome. Current systemic targeted therapies, such as denosumab, do not affect the neoplastic cells, resulting in relapse upon treatment discontinuation. Therefore, this study examined whether targeting the epigenome could eliminate the neoplastic cells from GCTB. We established four novel cell lines of neoplastic “stromal” cells that expressed the H3F3A p.G34W mutation. These cell lines were used to perform an epigenetics compound screen (n = 128), which identified histone deacetylase (HDAC) inhibitors as key epigenetic regulators in the neoplastic cells. Transcriptome analysis revealed that the neoplastic cells expressed all HDAC isoforms, except for HDAC4. Therefore, five HDAC inhibitors targeting different HDAC subtypes were selected for further studies. All GCTB cell lines were very sensitive to HDAC inhibition in both 2D and 3D in vitro models, and inductions in histone acetylation, as well as apoptosis, were observed. Thus, HDAC inhibition may represent a promising therapeutic strategy to eliminate the neoplastic cells from GCTB lesions, which remains the paramount objective for GCTB patients who require life-long treatment with denosumab.